Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280241 · ClinicalTrials.gov registry record · Phase 2
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00280241 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 65 participants.
The verdict
NCT00280241, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combination.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280241
The ClinicalTrials.gov registry entry for NCT00280241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00280241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280241 about?
NCT00280241 is a clinical study titled "Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia". This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combin...
What is the current status of trial NCT00280241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2004-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00280241?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT00280241?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.